Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

HIV Protease Inhibitors [MoA]

Known as: HIV Protease Inhibitors, Human Immunodeficiency Virus Protease Inhibitors 
National Institutes of Health

Related topics

Related topics

27 relations
AmprenavirAtazanavirAtazanavir sulfateErgotamine
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Effects of Human Immunodeficiency Virus Protease Inhibitors on the Intestinal Absorption of Tenofovir Disoproxil Fumarate In Vitro
ABSTRACT Human immunodeficiency virus protease inhibitors (PIs) modestly affect the plasma pharmacokinetics of tenofovir (TFV… Expand
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Highly Cited
2007
Highly Cited
2007
Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions
Although many of the clinically significant drug interactions of the anti-human immunodeficiency virus (HIV) protease inhibitors… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Highly Cited
2006
Highly Cited
2006
Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria
ABSTRACT Parasite resistance to antimalarial drugs is a serious threat to human health, and novel agents that act on enzymes… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2004
Highly Cited
2004
HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
Breast cancer resistance protein (BCRP) is a recently discovered ATP-binding cassette drug transporter. Hence, the full spectrum… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2003
Highly Cited
2003
Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.
The use of highly active antiretroviral therapy in persons with acquired immunodeficiency syndrome has reduced the prevalence of… Expand
Highly Cited
2002
Highly Cited
2002
Intracellular Accumulation of Human Immunodeficiency Virus Protease Inhibitors
ABSTRACT Intracellular accumulation of the protease inhibitors (PIs) saquinavir (SQV), ritonavir (RTV), and indinavir (IDV) was… Expand
Highly Cited
2001
Highly Cited
2001
Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction
Background—Human immunodeficiency virus protease inhibitors (HIV PIs) are associated with hyperlipidemia, hyperglycemia, and… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
1999
Highly Cited
1999
In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.
Highly active antiretroviral therapy that includes human immunodeficiency virus (HIV) aspartyl protease inhibitors (PIs) causes a… Expand
Highly Cited
1998
Highly Cited
1998
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir *
To assess the pharmacokinetic interaction between ritonavir and saquinavir. 
Review
1997
Review
1997
A 'second life' agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome.
Seldom in the history of medicine has an entire generation of patients with an incurable, progressive, and ultimately fatal… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE